Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBI 318

Next Previous
Drug Profile

IBI 318

Alternative Names: IBI-318

Latest Information Update: 28 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Innovent Biologics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Extranodal NK-T-cell lymphoma; Squamous cell cancer
  • Phase I Liver cancer
  • No development reported Haematological malignancies; Small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Combination therapy, Second-line therapy or greater) in China (IV, Injection)
  • 24 Mar 2023 Innovent Biologics terminates a phase I/II trial in Squamous cell cancer (cutaneous) (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV, Infusion) due to the company's development strategy adjustment, Innovent Biologics has decided not to continue this study after consultation with investigators (NCT04611321)
  • 16 Mar 2023 Innovent Biologics terminates a phase Ib trial in Liver cancer (In adults, In the elderly) in China (IV) due to the company development strategy adjustment, the company decided not to continue the study after consultation with investigators (NCT04635527)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top